Search
for
Sort by
Research 121–150 of 1000+
- 69 Risk-benefit appraisal of systemic JAK inhibitors for alopecia areata: a comprehensive meta-analysis assessing safety and adverse effects
- 151 Efficacy and adverse effects of oral Janus kinase inhibitor (JAKi) use in patients with lichen planopilaris: a retrospective case series and systematic review
- Screening for latent infectious disease in patients with alopecia areata before initiating JAK inhibitors therapy: a single-center real-world retrospective study
- Scarring hair follicle destruction is driven by the collapse of EGFR-protected JAK-STAT1-sensitive stem cell immune privilege
- 43647 Treatment of Refractory Folliculitis Decalvans with the Topical JAK Inhibitor Tofacitinib
- JAK inhibitor deuruxolitinib shows encouraging hair re-growth in alopecia areata
- The Triumph of JAK Inhibitors for the Treatment of Alopecia Areata
- A Comprehensive Literature Review of JAK Inhibitors in Treatment of Alopecia Areata
- JAK inhibitors for the treatment of alopecia areata
- 706 Predictive modeling of patient response to JAK/STAT inhibitors and dynamic patient-matching
- 865 Conditional ablation of JAK-STAT5 signaling induces anagen hair growth
- 546 Gene expression signatures and ALADIN score correlates with response of alopecia areata patients to treatment with JAK inhibitors
- Are Janus kinase (JAK) inhibitors beneficial in the treatment of androgenic alopecia?
- Efficacy of JAK 1/2 inhibition in the treatment of diffuse non-scarring alopecia due to systemic lupus erythematosus
- WNT5A drives interleukin-6-dependent epithelial–mesenchymal transition via the JAK/STAT pathway in keloid pathogenesis
- Mesenchymal Stem Cells Antagonize IFN-Induced Proinflammatory Changes and Growth Inhibition Effects via Wnt/β-Catenin and JAK/STAT Pathway in Human Outer Root Sheath Cells and Hair Follicles
- Comparative efficacy and safety of systemic steroids, oral JAK inhibitors and Contact Immunotherapy in the Treatment of severe alopecia areata: a systematic review and network meta-analysis
- JAK kinase pathway inhibitor drugs in patients with moderate-to-severe alopecia: a real-world experience
- Inhibition of JAK-STAT Signaling with Baricitinib Reduces Inflammation and Improves Cellular Homeostasis in Progeria Cells
- Baricitinib-loaded EVs promote alopecia areata mouse hair regrowth by reducing JAK-STAT-mediated inflammation and promoting hair follicle regeneration
- 1359 Hair growth is induced by blockade of macrophage-derived oncostatin M and downstream JAK-STAT5 signaling in hair follicle stem cells
- 705 Particulate matter induces inflammatory response in human outer root sheath cells via oxidative stress-dependent MAPK and JAK-STAT signaling pathways
- Safety of oral JAK inhibitors in treating alopecia areata: a systematic review and network meta-analysis
- Review of the Literature: Topical JAK Inhibitors Showing Promise for Hair Loss!
- 18883 Androgenetic alopecia pattern hair regrowth in patients with alopecia areata treated with oral JAK inhibitors
- Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata
- 126 Itch of Dermatomyositis treated with topical JAK inhibitor
- Selective JAK 1 inhibition with upadacitinib as a potential treatment for coexistent severe atopic dermatitis and alopecia areata
- The new era of JAK inhibitors: Impelling updates in Alopecia Areata Guideline
- Efficacy of JAK inhibitors in the treatment of alopecia: A case report of 10 patients